
FDA free to pursue semaglutide compounders after latest court ruling
A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo Nordisk’s popular drug semaglutide, opening the door for the US Food and Drug Administration (FDA) to take enforcement action. US District …